Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease

A Focus on Early Phase Clinical Drug Development

  • Andrew J. Krentz
  • Christian Weyer
  • Marcus Hompesch

Table of contents

  1. Front Matter
    Pages i-xi
  2. Review of Clinical Investigative Methods

    1. Front Matter
      Pages 1-1
    2. Andrew J. Krentz, Christian Weyer, Marcus Hompesch
      Pages 3-35
    3. Sten Madsbad, Jens J. Holst
      Pages 37-74
    4. Andrew J. Krentz, Christian Weyer, Marcus Hompesch
      Pages 75-100
    5. Klaas R. Westerterp
      Pages 101-119
    6. Catherine Gibbons, John E. Blundell
      Pages 121-140
    7. Olof Eriksson, Paul Hockings, Edvin Johansson, Lars Johansson, Joel Kullberg
      Pages 161-189
    8. Carine Beysen, Thomas E. Angel, Marc K. Hellerstein, Scott M. Turner
      Pages 211-243
    9. Harald Grallert, Carola S. Marzi, Stefanie M. Hauck, Christian Gieger
      Pages 309-347
  3. Preclinical Drug Development and Transitioning to Clinical Studies

    1. Front Matter
      Pages 349-349
    2. Henrik H. Hansen, Gitte Hansen, Thomas Secher, Michael Feigh, Sanne S. Veidal, Keld Fosgerau et al.
      Pages 369-403
    3. Fernando Bril, Marta Iruarrizaga-Lejarreta, Cristina Alonso
      Pages 405-421
    4. Marta Iruarrizaga-Lejarreta, Fernando Bril, Mazen Noureddin, Pablo Ortiz, Shelly C. Lu, José M. Mato et al.
      Pages 423-448
    5. Farzaneh Maleki, Puneet Gaitonde, Shannon Miller, Mirjam N. Trame, Paul M. Coen, Parag Garhyan et al.
      Pages 449-466
    6. Geoffrey A. Walford, S. Aubrey Stoch
      Pages 467-486
    7. Linda A. Morrow, Andrew J. Krentz
      Pages 517-538
  4. Back Matter
    Pages 539-556

About this book


This book aims to aid the selection of the most appropriate methods for use in early phase (1 and 2) clinical studies of new drugs for diabetes, obesity, non-alcoholic fatty liver disease (NAFLD) and related cardiometabolic disorders.

Clinical research methods to assess the pharmacokinetics and pharmacodynamics of new diabetes drugs, e.g. the euglycemic clamp technique, have become well-established in proof-of-mechanism studies.  However, selection of the most appropriate techniques is by no means straightforward. Moreover, the application of such methods must conform to the regulatory requirements for new drugs.

This book discusses the need for new pharmacotherapies for diabetes, obesity and NAFLD and the molecular targets of drugs currently in development.  Emerging technologies including functional imaging, circulating biomarkers and omics are considered together with practical and ethical issues pertaining to early phase clinical trials in subjects with cardiometabolic disorders.

Translational Research Methods in Diabetes, Obesity, and Non-Alcoholic Fatty Liver Disease is of interest to biomedical scientists, pharmacologists, academics involved in metabolic research and clinicians practicing in these specialties.


obesity diabetes non-alcoholic fatty liver disease glucose-lowering drugs glucose clamp insulin resistance cardiometabolic disease

Editors and affiliations

  • Andrew J. Krentz
    • 1
  • Christian Weyer
    • 2
  • Marcus Hompesch
    • 3
  1. 1.ProScientoChula VistaUSA
  2. 2.ProScientoChula VistaUSA
  3. 3.ProScientoChula VistaUSA

Bibliographic information